KR20160149570A - Method for preparing schisandra chinensis comprising lignan in high concentration - Google Patents
Method for preparing schisandra chinensis comprising lignan in high concentration Download PDFInfo
- Publication number
- KR20160149570A KR20160149570A KR1020150086752A KR20150086752A KR20160149570A KR 20160149570 A KR20160149570 A KR 20160149570A KR 1020150086752 A KR1020150086752 A KR 1020150086752A KR 20150086752 A KR20150086752 A KR 20150086752A KR 20160149570 A KR20160149570 A KR 20160149570A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- omija
- omiza
- electrodialysis
- lignan
- Prior art date
Links
- 229930013686 lignan Natural products 0.000 title claims abstract description 41
- 235000009408 lignans Nutrition 0.000 title claims abstract description 41
- 150000005692 lignans Chemical class 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 31
- 240000006079 Schisandra chinensis Species 0.000 title 1
- 235000008422 Schisandra chinensis Nutrition 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 71
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims abstract description 48
- 238000000909 electrodialysis Methods 0.000 claims abstract description 43
- 241001400472 Omiza Species 0.000 claims abstract description 35
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 31
- 150000007524 organic acids Chemical class 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 9
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 102000002464 Galactosidases Human genes 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 4
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims 1
- 239000000243 solution Substances 0.000 description 16
- 230000008569 process Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 229940093915 gynecological organic acid Drugs 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- -1 Lignan compound Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229920005610 lignin Polymers 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000003011 anion exchange membrane Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- ZWRRJEICIPUPHZ-MYODQAERSA-N gomisin a Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@](C)(O)[C@@H](C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-MYODQAERSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003014 ion exchange membrane Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000009441 vascular protection Effects 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- ZWRRJEICIPUPHZ-UHFFFAOYSA-N schisandrol B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)(O)C(C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-UHFFFAOYSA-N 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2132—Other phenolic compounds, polyphenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
More particularly, the present invention relates to a method for producing an extract of Omiza containing a high concentration of lignan, and more particularly, to a method for preparing an extract of Omiza containing high concentrations of lignans by hydrolyzing an organic acid after electrodialysis of the Omiza extract, To a high concentration of lignans which can improve the high value of the omija.
Description
More particularly, the present invention relates to a method for producing an extract of Omiza containing a high concentration of lignan, and more particularly, to a method for preparing an extract of Omiza containing high concentrations of lignans by hydrolyzing an organic acid after electrodialysis of the Omiza extract, To a high concentration of lignans which can improve the high value of the omija.
Schizandra chinensis Baillon ( Schizandra chinensis Baillon ) is the main medicinal plant used for raw materials and food raw materials. It is a mature fruit of Schizandra chinensis Baillon such as deciduous wood belonging to the Schizandraceae family.
Omija has five flavors and unusual orientations in sweet, spicy, spicy, spicy, and salty, and has been widely used as an omija tea, Omija liquor, and Omiza lacquer.
The main active ingredients contained in Omiza are gomisin A, B, C, D, E, F, G, K3, N, J, schizandrin A, B, C, schisandrol Lignan compound which contains various components such as oil, essential oil and pigment and has various pharmacological functions including inhibition of hepatotoxicity and is used as a raw material for medicines and food. Recently, studies on the antioxidative and antimicrobial activities of the extracts of omija and lignans have been reported, and it has been reported that the olanzoline has a pharmacological effect such as hypoglycemic action, anti-ulcer action, chronic hepatitis treatment effect, .
The lignans can be classified into four main categories according to their therapeutic properties: adaptogenic action, liver protection, liver stabilization and liver regeneration.
The augotagenic action of lignans has a unique mechanism of action and includes lignans which act as energizers, nervous system promoters, oxygenators, immunomodulators, antioxidants and skin protectants. The lignan has been found to reduce hyperlipemia and significantly inhibit the progression of arteriosclerosis. Lignans is also closely linked to increased levels of ascorbic acid in the liver, inhibition of NADPH oxidation and lipid peroxidation, and the induction of hepatic microsomal cytochrome P-450 enzymes. Liver protection Lignans are known to protect the liver from cholestasis induced by toxic substances. Furthermore, it has been demonstrated that lignan compounds contribute to liver regeneration through induction of hepatocyte growth factor mRNA transcription, promotion of hepatocyte proliferation, and increased blood flow to the liver. It is also known that the above lignan induces an increase in the activity of mitochondrial reductase glutathione and the level of glutathione in mitochondria in order to promote the regeneration ability through synthesis of intercellular glycogen and decrease of glutathione.
As the effectiveness of lignan is proved, the demand for lignan is increasing. Therefore, it is necessary to further study a method of extracting lignan at a high yield, economically and easily.
In order to solve the problems of the prior art as described above, the present invention provides a method for producing lignan, which comprises high concentration of lignan, which is a functional ingredient, by hydrolyzing an enzyme, And a method for producing the same.
Another object of the present invention is to provide a method for preparing an extract of Omiza, which can improve the high added value of Omija and further contains lignans which can be utilized for the development of various functional foods and natural materials.
It is another object of the present invention to provide an Omija extract containing a high concentration of lignans excellent in anticancer, antiviral, anti-inflammatory and vascular protection functions, and an Omija liquid containing the same.
In order to accomplish the above object, the present invention provides a method for preparing an omeprazole extract, And a step of treating a hydrolytic enzyme with an extract of Schizandra chinensis from which the free acid has been separated. The present invention also provides a method for producing an extract of Schizandra chinensis containing a high concentration of lignans.
The electrodialysis can be performed by using at least one electrode solution selected from sodium chloride (NaCl), sodium carbonate (NaCO 3 ), sodium sulfate (Na 2 SO 4 ) and potassium chloride (KCl) at a room temperature under a condition of 10 to 20 V for 50 to 100 minutes And the current density is changed to 50 to 150 A / m < 2 >.
The hydrolytic enzyme treatment may be performed by adding 0.01 to 5.0% by weight of β-glucosidase, galactosidase and the like to the total weight of the extract of Omiza, and the treatment is carried out at 25 to 30 ° C. for 1 to 2 hours And the reaction can be carried out.
The present invention also provides an extract of Omija, which is prepared by the above method and has an increase in lignin content by 20% or more as compared with before electrodialysis and hydrolysis.
The present invention also provides an Omija liquid comprising the above-mentioned Omija extract as an active ingredient.
According to the present invention, the extract of Schizandra chinensis can be electrodialyzed, the organic acid can be separated and treated with the hydrolytic enzyme, and the lignan, which is a functional ingredient, can be contained at a high concentration and the absorption of lignans can be promoted. In addition, according to the present invention, it is possible to improve the high added value of Omija and further contribute to the development of various functional foods and natural materials.
Figure 1 shows chromatograms of a standard solution, a control solution and an experimental solution.
2 is a graph showing the results of the calibration curve of the standard solution, seedrazine.
3 is a graph showing a calibration curve of a standard solution of hypermucin A as a standard solution.
Hereinafter, the present invention will be described in detail.
The method of the present invention includes a step of electrodialysis of an extract of Omija to separate an organic acid, and a step of treating a hydrolytic enzyme with an extract of Omija, from which the free acid has been separated. The Omija extract prepared at this stage has a high concentration of lignans do.
Omiza contains a high content of phenolic compounds, and the main component of these phenolic compounds is lignans, which are present in the form of glycosides linked to some sugars. Accordingly, in the present invention, a large amount of lignan can be separated by separating a phenol-based glycoside into a sugar and an aglycone through a hydrolytic enzyme treatment to prepare an extract of Omiza containing lignans in high purity. In addition, the present invention can maximize the hydrolytic enzyme treatment effect by inhibiting the enzyme activity inhibition at low pH by separating the organic acid in the omiza by electrodialysis prior to the hydrolytic enzyme treatment.
The Omiza extract used for the electrodialysis of the present invention can be extracted by a conventional method. As the extraction solvent, distilled water or a lower alcohol such as ethanol, methanol, butanol, acetone, ethyl acetate, dichloromethane, or an intermediate polar organic solvent may be used alone or as a mixture of two or more kinds. In particular, It is better to extract it.
Specifically, the above-mentioned Omiza extract was mixed with water at a weight ratio (w / v) of 1: 10 with respect to the weight of dried omija, and then extracted at 80 ° C for 3 hours or extracted with ethanol, methanol, butanol, acetone, ethyl acetate, dichloromethane Of lower alcohol or an intermediate polar organic solvent as an extraction solvent, and extracting solvent to the weight of dried omija at a weight ratio (w / v) of 1:10, and then extracting at room temperature for 24 hours. The extract can be prepared by a conventional extraction method such as a low temperature extraction method, a room temperature extraction method, an ultrasonic extraction method, or a reflux extraction method. The resulting extract is filtered with a filter paper, and the obtained filtrate is freeze-dried, .
The above-extracted Omiza extract can be separated into high purity through various conventional separation methods as necessary. Separation methods such as solvent distribution, precipitation separation, recrystallization, and column chromatography can be used as separation methods usable at this time.
The thus-prepared Omiza extract is neutralized to have a pH of about 5.5. At this time, the neutralization process may be performed using 0.1N NaOH in the extract of Omija, or 2mL of 1 mM NaNO 2 solution may be added, and the treatment may be performed using 0.1N HCl and 0.2M citrate buffer.
Then, the above-mentioned Omija extract is subjected to electrodialysis to separate the organic acid contained in the Omija.
The electrodialysis can be performed using a conventional electrodialyzer. Specifically, the electrodialysis can be performed using an electrodialyzer in which a cation exchange membrane and an anion exchange membrane usable for food are arranged in order, at room temperature, at 10 to 20 V for 50 to 100 minutes And the current density can be changed by 50 to 150 A / m < 2 >. At this time, an aqueous sodium chloride solution can be added to the electrodialyzer so that initial electricity flows well. As the electrode solution, at least one selected from sodium chloride (NaCl), sodium carbonate (NaCO 3 ), sodium sulfate (Na 2 SO 4 ) and potassium chloride (KCl) can be used. In particular, a solution of sodium carbonate (NaCO 3 ) It is good.
Electrodialysis is a process for ion-exchanging, purifying, and concentrating an electrolyte present in an aqueous solution by passing ions through an ion exchange membrane using a potential difference. The electrodialysis process facilitates the production of high purity organic acids by not only separating the organic acids from the fermentation broth but also reducing the cost of energy required for the concentration of organic acids in the lower process. In addition, electrodialysis is a very eco-friendly process because it does not generate any impurities caused by the process, unlike a general refining process.
The main parameters affecting the separation process of organic acids in electrodialysis are the current density, the concentration of the raw solution, and pH. The electrodialysis condition in the present invention is a principle of converting a salt-like substance into an acid and an alkali form using a bipolar membrane. The hydrogen ions and the hydroxide ions generated on both surfaces of the bipolar membrane are transferred to the feed compartment and the permeate compartment, respectively. In order to match the ion concentration in the compartments, the ions having an inner charge pass through the ion exchange membrane and move to the other compartment. The generated acid is accumulated.
Therefore, in the present invention, by using the electrodialysis method as described above, it is possible to effectively separate (remove) the organic acid contained in the omisza at low cost.
The degree of separation (removal) of the organic acid by electrodialysis can be confirmed by measuring the electrical conductivity and pH.
When the electrodialysis is performed as described above, the organic acid contained in the omija can be separated, and the omija extract in which the organic acid is separated can maintain the pH above a certain level, thereby inhibiting the hydrolytic enzyme activity inhibition due to the low pH. Therefore, if the electrodialysis is performed, the effect of the hydrolytic enzyme treatment can be further maximized. In addition, since the electrodialysis process does not perform chemical neutralization, the problem of metal ions remaining from the alkali substance used in neutralization can also be prevented through the electrodialysis process.
As described above, hydrolytic enzymes are applied to the extract of Omija, which is obtained by separating organic acids through electrodialysis.
The hydrolytic enzymes can be used without limitation as long as they are enzymes capable of separating glycosides from sugar and aglycons. Specifically, beta-glucosidase, galactosidase and the like are used .
The hydrolytic enzyme is added in an amount of 0.01 to 5.0% by weight, preferably 0.1% by weight, based on the total weight of the extract, and the reaction is preferably carried out at 25 to 30 ° C for 1 to 2 hours. When the hydrolytic enzyme is added in an amount of less than 0.01% by weight, the hydrolysis efficiency may be insufficient. When the hydrolytic enzyme is added in an amount exceeding 5.0% by weight, the hydrolysis efficiency is not significantly changed.
After the hydrolytic enzyme treatment, the extract of Omiza increased the lignin content by 20% or more as compared with that before the electrodialysis and hydrolytic enzyme treatment, thereby preparing an Omija extract having enhanced anticancer, antiviral, anti-inflammatory and vascular protection functions .
The present invention also provides an Omija liquid comprising the above-prepared Omija extract as an active ingredient.
According to the present invention, the above-mentioned Omiza liquid may further comprise an Omija water extract together with an Omiza extract containing a high concentration of lignan as a functional ingredient.
Preferably, the Omiza extract is contained in an amount of 2 to 10% by weight (v / v), more preferably 5% by weight, based on the total volume of the omithine solution. If the content is less than 2% by weight, the functional effect of lignans may be insignificant. If the content is more than 10% by weight, the effect of lignan relative to the usage amount is relatively low and there is no significant change in sensory characteristics and functionality, May lead to an increase in product prices. In particular, when added at 5% by weight based on the total volume of the omiza solution, the above-mentioned Omiza extract is superior in sensory properties and most effective in antibacterial activity.
In addition, the above-mentioned Omija hot-water extract may be prepared by extracting water at 30-40 ° C. with water by an ordinary method according to a conventional method.
Hereinafter, the present invention will be described in more detail with reference to examples. These embodiments are for purposes of illustration only and are not intended to limit the scope of protection of the present invention.
Example 1
In September, 2012, one of the omija harvested at Mungyeong was selected to have a size of 0.7-0.9 mm and dried at 20 ° C at low temperature. 1,100 ml of distilled water was added to 110 g of the dried omija as an extraction solvent and extracted at 30 ° C to prepare an Omija extract (pH 2.7).
The pH of the Omiza extract was adjusted to 5.5, and 500 ml of Omiza extract was placed in an electrodialyzer (MicroAcylizer-S3, Asahi Chemical Co., Shizuoka, Japan) for electrodialysis at room temperature and 12V for 180 minutes. At this time, the electrodialyzer used an electrodialyzer in which five cation exchange membranes (AMX-SB) and anion exchange membranes (CMX-SB) were arranged in order. In the concentrating chamber of the electrodialyzer, 500 ml of 0.5% sodium chloride aqueous solution was added for initial current flow, and 500 ml of 5% sodium carbonate solution was used as the electrode solution. The electroconductivity was measured to determine the degree of elimination of neutralized organic acid, and it was confirmed that 95% or more of the organic acid contained in the extract of Omija was separated, and the electrodialysis was terminated.
After the electrodialysis, 0.1% by weight of β-glucosidase and galactosidase were added to the Omiza extract, respectively, and the mixture was reacted at 25 to 30 ° C. for 1 to 2 hours for hydrolytic enzyme treatment.
Experimental Example 1. Determination of Organic Acid Separation by Electrodialysis
The electrical conductivity and organic acid were measured in order to confirm the degree of separation of organic acid by the electrodialysis process in the Example 1.
First, in Example 1, the extract of Omiza before electrodialysis was filtered using Watson filter paper (20μ), and the electrical conductivity and pH immediately after extraction were measured using an electric conductivity meter. Thereafter, the pH of the Schizosacralis japonica extract was adjusted to 5.5, and then the electrical conductivity and pH were measured. After completion of the electrodialysis, the electrical conductivity and pH were measured, and the results are shown in Table 1 below.
In addition, 0.1 M sodium hydroxide solution was titrated in 10 ml of the extract using an Omija extract before electrodialysis and an Omija extract after completion of electrodialysis until the pH reached 8.3, and the acidity was measured according to the following formula (1). The results are shown in Table 2 below.
[Equation 1]
As shown in Tables 1 and 2, when the electrodialysis process was performed prior to the hydrolytic enzyme treatment of Omiza extract according to the present invention, the electrical conductivity fell from 17.58 mS / cm to 1.62 mS / cm, , And the acidity of the extract of Omija was 0.0219, which was about 0.0012 after electrodialysis, indicating that about 95% of the organic acid was isolated.
Experimental Example 2. Measurement of Lignan Content
In order to measure the content of lignans contained in the extract of Omija after the electrodialysis and hydrolytic enzyme treatment in Example 1, the following experiment was conducted.
First, the hydrolytic enzyme-treated Omija extract of Example 1 was subjected to electrodialysis and then lyophilized and powdered. 500 mg of the powder was dissolved in 20 ml of methanol, sonicated for 20 minutes and filtered. After filtration, 20 ml of methanol was added to the residue, and the mixture was subjected to ultrasonic extraction for 20 minutes and filtration. The filtrate was combined and the filtrate was adjusted to 50 ml with methanol and filtered through a 0.45 μm nylon membrane syringe filter.
As the reference material, the superficial lignin A and sizindrin were dissolved in methanol (Duksan, HPLC grade), and the stock solution was appropriately diluted with methanol and used as a standard solution. As a control, the omija extract prepared in Example 1 was lyophilized and powdered. 500 mg of the powder was dissolved in 20 ml of methanol, sonicated for 20 minutes and filtered. After filtration, 20 ml of methanol was added to the residue, and the mixture was subjected to ultrasonic extraction for 20 minutes and filtration. The filtrate was combined and the filtrate was adjusted to 50 ml with methanol and filtered through a 0.45 μm nylon membrane syringe filter.
C18 column. High glomerulin A and sizzydrine were detected in the control and experimental groups at 254 nm. High myrin A and sizzardine content in the samples were measured using a standard curve. The analysis was performed according to the conditions shown in Table 3 below.
The chromatograms of the standard solution, the control solution and the test solution are shown in FIG. 1, and the calibration curve results of the standard solution are shown in Table 4, FIGS. 2 and 3, and the control solution and the experimental solution Of the present invention are shown in Tables 5 and 6. < tb > < TABLE > The following results were obtained through five repeated experiments.
&Quot; (2) "
As shown in Tables 5 and 6, in the control group without electrodialysis and hydrolytic enzyme treatment, the content of sizzardine was 0.056 ± 0.0005 mg / g, and the content of hypermucin A was 0.11 ± 0.0002 mg / g. On the other hand, in the experimental group of Example 1 in which hydrolytic enzyme treatment was performed according to the present invention, the sizzolidine content was 0.067 ± 0.0039 mg / g and the hypericin A content was 0.013 ± 0.0007 mg / g. From these results, it can be seen that the hydrolysis enzyme-treated Omiza extract according to the present invention increased the lignan content by about 20% as compared with the Omiza extract without electrodialysis and hydrolytic enzyme treatment.
Although the present invention has been described in terms of the preferred embodiments mentioned above, it is possible to make various modifications and variations without departing from the spirit and scope of the invention. It is also to be understood that the appended claims are intended to cover such modifications and changes as fall within the scope of the invention.
Claims (9)
Treating the hydrolytic enzyme with an extract of Schizandra chinensis isolated from the free acid;
Wherein the lignan is present at a high concentration.
The extract of Omiza is prepared by adding at least one solvent selected from the group consisting of distilled water, ethanol, methanol, butanol, acetone, ethyl acetate and dichloromethane to a weight ratio of dried seaweed to a dry weight ratio of 1:10 (w / v) A method for producing an Omija extract containing a high concentration of lignans.
The electrodialysis can be performed by using at least one electrode solution selected from sodium chloride (NaCl), sodium carbonate (NaCO 3 ), sodium sulfate (Na 2 SO 4 ) and potassium chloride (KCl) at a room temperature under a condition of 10 to 20 V for 50 to 100 minutes Wherein the current density is changed in a range of 50 to 150 A / m < 2 >.
Wherein the hydrolytic enzyme is any one selected from the group consisting of beta-glucosidase, galactosidase, and mixtures thereof.
Wherein the hydrolytic enzyme treatment is carried out by adding 0.01 to 5.0% by weight based on the total weight of the Schizandra chinensis extract and reacting at 25 to 30 ° C for 1 to 2 hours to prepare an omija extract containing high concentrations of lignans .
Wherein the extract of Omiza after the hydrolytic enzyme treatment has a lignan content increased by at least 20% as compared with that before treatment with electrodialysis and hydrolytic enzymes.
Wherein the Omiza extract is contained in an amount of 2 to 10% by weight (v / v) based on the total volume of the Omija liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150086752A KR20160149570A (en) | 2015-06-18 | 2015-06-18 | Method for preparing schisandra chinensis comprising lignan in high concentration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150086752A KR20160149570A (en) | 2015-06-18 | 2015-06-18 | Method for preparing schisandra chinensis comprising lignan in high concentration |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20160149570A true KR20160149570A (en) | 2016-12-28 |
Family
ID=57724416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150086752A KR20160149570A (en) | 2015-06-18 | 2015-06-18 | Method for preparing schisandra chinensis comprising lignan in high concentration |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20160149570A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110027339A (en) | 2009-09-10 | 2011-03-16 | 부산대학교 산학협력단 | Method for extraction of lignan from seed of schisandra chinensis |
-
2015
- 2015-06-18 KR KR1020150086752A patent/KR20160149570A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110027339A (en) | 2009-09-10 | 2011-03-16 | 부산대학교 산학협력단 | Method for extraction of lignan from seed of schisandra chinensis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gosset-Erard et al. | Identification of punicalagin as the bioactive compound behind the antimicrobial activity of pomegranate (Punica granatum L.) peels | |
Reddy et al. | Antioxidant, antimalarial and antimicrobial activities of tannin-rich fractions, ellagitannins and phenolic acids from Punica granatum L. | |
JP5615966B2 (en) | Piceatannol-containing composition | |
Delgado De La Torre et al. | Characterization and comparison of wine lees by liquid chromatography–mass spectrometry in high-resolution mode | |
CN102441040A (en) | Preparation method of cistanche deserticola phenylethanoid glycosides | |
CN105732250B (en) | A kind of preparation method of high-purity grifola frondosus weight polyphenol fraction | |
Matsuta et al. | Biological activity of luteolin glycosides and tricin from Sasa senanensis Rehder | |
EP2828276B1 (en) | Rutin-rich extract of uncaria elliptica and method of preparation | |
Hseu et al. | Antrodia salmonea in submerged culture exhibits antioxidant activities in vitro and protects human erythrocytes and low-density lipoproteins from oxidative modification | |
Li et al. | Targeted phenolic analysis in Hericium erinaceum and its antioxidant activities | |
Bai et al. | The research progress of extraction, purification and analysis methods of phenolic compounds from blueberry: a comprehensive review | |
Qiu et al. | Antioxidant and antigenotoxic activities of ethanol extracts from Rhus chinensis Mill leaves | |
KR101453609B1 (en) | Novel Hemiterpene Glucoside Compounds Isolated from the Leaves of Spiraea prunifolia and Anti-Oxidative and Anti-Inflammatory Use Thereof | |
EP3888645A1 (en) | Method for producing extract of red shiso leaves | |
Zhao et al. | Effects of different extraction methods on the properties of pine cone polysaccharides from Pinus koraiensis | |
CN101823964A (en) | Technology for preparing chlorogenic acid in viburnum sargentii koehne leaves | |
Kim et al. | Identification of 5-hydroxy-3, 6, 7, 8, 3, 4-hexamethoxyflavone from Hizikia fusiforme involved in the induction of the apoptosis mediators in human AGS carcinoma cells | |
KR20160149570A (en) | Method for preparing schisandra chinensis comprising lignan in high concentration | |
KR20190101063A (en) | Composition containing natural material extract for preventing and improving respiratory organ disease | |
Liu et al. | Preparing apigenin from leaves of Adinandra nitida | |
CN105748547B (en) | A method of extracting isolating active component from saussurea involucrata cell culture | |
Li et al. | Structure and accumulation of phenolics in elicited Echinacea purpurea cell cultures | |
JP4308714B2 (en) | Process for producing natural product-derived glyceroglycolipid | |
Kang et al. | Evaluation of the peroxynitrite scavenging activity of heat-processed ginseng | |
JP3026435B1 (en) | Leukemia cell growth inhibitor and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |